<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014777</url>
  </required_header>
  <id_info>
    <org_study_id>18-0501</org_study_id>
    <nct_id>NCT04014777</nct_id>
  </id_info>
  <brief_title>Study of NGM621 in Participants With Geographic Atrophy</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose
      escalation study in participants with Geographic Atrophy secondary to Age-related Macular
      Degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number and percent of patients reporting treatment emergent adverse events (TEAEs) by cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of NGM621</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual and mean serum NGM621 concentration data by cohort.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>NGM621 Cohort 1 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 single IVT injection Cohort-Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM621 Cohort 2 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 single IVT injection Cohort--Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM621 Cohort 3 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 single IVT injection Cohort--Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM621 Cohort 4 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM621 multiple IVT injection Cohort--Dose 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 1</description>
    <arm_group_label>NGM621 Cohort 1 Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 2</description>
    <arm_group_label>NGM621 Cohort 2 Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 3</description>
    <arm_group_label>NGM621 Cohort 3 Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM621</intervention_name>
    <description>NGM621 Dose 4</description>
    <arm_group_label>NGM621 Cohort 4 Multiple Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. GA lesion size in the study eye of &gt;=2.5 mmÂ² as assessed by the central reading center

          2. BCVA - 54 to 4 letters (20/80 to 20/400 Snellen equivalent) using the standard ETDRS
             (Early Treatment of Diabetic Retinopathy Study) in the study eye at the Screening and
             Baseline visits; the fellow eye must have a BCVA of at least 69 letters (Snellen
             equivalent 20/40) at the Screening and Baseline visits

        Exclusion Criteria:

          1. GA in either eye because of cause other than AMD

          2. History or evidence of glaucoma or ocular hypertension in either eye as defined by
             investigator

          3. Visual impairment in the study eye due to causes other than GA

          4. Spherical equivalent of the refractive error in the study eye demonstrating more than
             -6 Diopters of myopia (prior to cataract or refractive surgery)

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

